Flupirtine
Trade name: katadolon
Small moleculeexperimental
Clinical trial activity
3 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2007 (NCT00623415)
Timeline
Indications
Mechanism of action
- Glutamate [NMDA] receptor subunit 3AANTAGONIST
GRIN3A antagonist
Chemistry & pharmacology
Loading structure…
SMILES
CCOC(=O)Nc1ccc(NCc2ccc(F)cc2)nc1N- Mol. weight
- 304.32 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL255044 ↗
- ChEMBLCHEMBL1256752 ↗
Also known as
- d 9998
- d-9998
- ethyl 2-amino-6-((p-fluorobenzyl)amino)-3-pyridinecarbamate
- ethyl n-(2-amino-6-((4-fluorophenyl)methylamino)pyridin-3-yl)carbamate
- flupirtine
- flupirtine
- flupirtine
- flupirtine
- flupirtine
- flupirtine
- flupirtine
- flupirtine maleate
- flupirtine maleate (1:1)
- flupirtin maleate
- flupirtin maleate
- flupirtin maleate
- flupirtin maleate
- flupirtin maleate
- flupirtin maleate
- katadolon
- katadolon
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01450865 | Phase 1 | Oct 1, 2009 | Ludwig Maximilians University |
| NCT01676246 | Phase 1 | May 1, 2008 | AWD.pharma GmbH & Co. KG, University of Greifswald |
| NCT00623415 | Phase 2 | Dec 1, 2007 | Bayer, Humboldt University |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AWD.pharma GmbH & Co. KG | For profit | 1 | 0 | 1 | 2008 |
| Bayer | For profit | 1 | 0 | 1 | 2007 |
| Humboldt University | Academic/Hospital | 1 | 1 | 1 | 2007 |
| Ludwig Maximilians University | Academic/Hospital | 1 | 1 | 1 | 2009 |
| University of Greifswald | Academic/Hospital | 1 | 1 | 1 | 2008 |
5 organizations
Page 1 / 1